Epidermolysis Bullosa (EB) Market Research Report present a detailed analysis of the market listing Epidermolysis Bullosa (EB) Epidemiology, Drug therapies and pipeline for study period from 2016-2018.

Epidermolysis Bullosa (EB) Market Size & Share | Epidermolysis Bullosa (EB) Market Research Report, Market Analysis, Market Growth, trends and Forecast

DelveInsight's 'Epidermolysis Bullosa (EB)&mdash;Market Insights, Epidemiology, and Market Forecast&mdash;2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of EB in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.
EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae. Epidermolysis bullosa usually is diagnosed in babies and children, but milder types can develop later in adulthood.
&nbsp;
EB may be inherited in either a dominant or recessive form. In dominant EB, one parent usually carries the gene and is affected by the condition themselves, while the birth of a child suffering from the recessive form is usually totally unexpected since both parents can carry the EB gene without displaying the condition themselves. In dominant EB, there is a 50% chance of passing the disorder to children: in recessive EB the chance is 25%.
&nbsp;
<h2>Geography Covered</h2>
&bull; The United States
&bull; EU5 (Germany, France, Italy, Spain, and the United Kingdom)
&bull; Japan
&nbsp;
Study Period: 2017-2028
&nbsp;
<h2>Epidermolysis Bullosa (EB)&mdash;Disease Understanding and Treatment Algorithm</h2>
Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma. To date, there is no treatment or cure for EB.&nbsp;
There are four major types of EB, depending on the location of the target proteins and level of the blisters: EB simplex (epidermolytic), junctional EB (lucidolytic), dystrophic EB (dermolytic), and Kindler syndrome (mixed levels of blistering). Apart from this when EB also occurs due to any defect in the immune system it is called epidermolysis bullosa acquisita (EBA).
&nbsp;
<h2>Epidermolysis Bullosa (EB) Epidemiology</h2>
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM, Total Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM, and Type-specific Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in 7MM) scenario of Epidermolysis Bullosa (EB) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, the total diagnosed cases of Epidermolysis Bullosa (EB) were found out to be 39,433 in 2017, in the 7MM. The number of Epidermolysis Bullosa (EB) cases in the 7MM is expected to increase during the study period of 2017-2028.?
&nbsp;
<h2>Epidermolysis Bullosa (EB) Drug Chapters</h2>
There is currently no cure for EB and treatments focus on preventing blisters or managing the wounds caused by the condition. There are different types of EB that are associated with blisters forming in different locations on the body and that vary in severity. Different treatments are used depending on the type of epidermolysis bullosa.
There are no EB-specific medications. Depending on the severity of the condition, doctors may recommend over-the-counter pain medication or may prescribe stronger painkillers, such as morphine, if needed. If the patient is experiencing chronic pain, then medicines such as amitriptyline, gabapentin or pregabalin may be prescribed. If a wound becomes infected, it may be treated with antibiotics. These can be applied as a topical lotion, a soaking solution, or taken as an oral tablet. Anti-inflammatory drugs such as corticosteroids may be prescribed to reduce pain from swallowing, making it easier to eat. With systemic corticosteroids, steroid-sparing agents, including colchicine, diaminodiphenyl sulfone (DDS, dapsone), methotrexate (MTX), azathioprine (AZA), cyclosporine (CSA), mycophenolate mofetil (MMF), and cyclophosphamide (CPA), have been reported in the treatment of EBA. Other therapeutic options, including high-dose intravenous Immunoglobulin (IVIG), rituximab (RTX), plasmapheresis and immune adsorption (IA), and extracorporeal photochemotherapy (ECP) also have been reported.
&nbsp;
<h2>Epidermolysis Bullosa (EB) Market Outlook</h2>
The market size of Epidermolysis Bullosa (EB) in seven major markets (7MM) is estimated to be USD 2,296.31 million in 2017. The United States accounts for the highest market size of Epidermolysis Bullosa, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain and the United Kingdom), and Japan. Among the EU5 countries, the UK had the highest market size with USD 195.25 million in 2017, while Spain had the lowest market size of Epidermolysis Bullosa with USD 35.99 million in 2017.
&nbsp;
<h2>Epidermolysis Bullosa (EB) Drugs Uptake</h2>
With the launch of emerging therapies that includes FCX-007 (Fibrocell Technologies), CCP-020 (Castle Creek Pharmaceuticals), RGN-137 (RegeneRx); AP-101 (Amryt Pharma), EB-101 (Abeona Therapeutics), KB103 (Krystal Biotech), and Ex-vivo expanded autologous with a COL7A1-encoding retroviral vector and LAMB3 encoding gene therapy (Holostem Terapie Avanzate), the market of EB is anticipated to change during the forecasted period (2019-2028).
&nbsp;
<h2>Epidermolysis Bullosa (EB) Report Insights</h2>
&bull; Patient Population by total diagnosed cases
&bull; Type-specific diagnosed population
&bull; Therapeutic Approaches
&bull; Pipeline Analysis
&bull; Market Size and Trends
&bull; Market Opportunities
&bull; Impact of upcoming Therapies
&nbsp;
<h2>Epidermolysis Bullosa (EB) Report Key Strengths</h2>
&bull; 10-Year Forecast
&bull; 7MM Coverage
&bull; Epidemiology Segmentation
&bull; Drugs Uptake
&bull; Highly Analyzed Market
&bull; Key Cross Competition
&nbsp;
<h2>Epidermolysis Bullosa (EB) Report Assessment</h2>
&bull; Current Treatment Practices
&bull; Unmet Needs
&bull; Detailed Pipeline Product Profiles
&bull; Market Attractiveness
&bull; Market Drivers and Barriers
&nbsp;
<h2>Key Benefits</h2>
&bull; This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving EB market
&bull; Organize sales and marketing efforts by identifying the best opportunities for EB market
&bull; To understand the future market competition in the EB market.

1. Key Insights
2. Epidermolysis Bullosa (EB) Market Overview at a Glance
2.1. Market Share (%) Distribution of Epidermolysis Bullosa (EB) in 2017
2.2. Market Share (%) Distribution of Epidermolysis Bullosa (EB) in 2028
3. Epidermolysis Bullosa (EB): Disease Background and Overview
3.1. Introduction
3.2. Causes of Epidermolysis Bullosa
3.3. Signs and Symptoms of Epidermolysis Bullosa
3.4. Classification of Epidermolysis Bullosa
3.5. Pathophysiology of Epidermolysis Bullosa
3.6. Genetic Bases of Epidermolysis Bullosa
3.7. Diagnosis of Epidermolysis Bullosa
3.8. Diagnostic Guidelines
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of Epidermolysis Bullosa
4.3. 7MM Diagnosed Prevalent Patient Population of Epidermolysis Bullosa
4.4. 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa
5. Country Wise-Epidemiology of Epidermolysis Bullosa
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Epidermolysis Bullosa in the United States
5.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United States
5.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Prevalent Cases of Epidermolysis Bullosa in Germany
5.2.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in Germany
5.2.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Prevalent Cases of Epidermolysis Bullosa in France
5.2.2.3. Diagnosed Prevalence of Epidermolysis Bullosa in France
5.2.2.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Italy
5.2.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Italy
5.2.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Prevalent Cases of Epidermolysis Bullosa in Spain
5.2.4.3. Diagnosed Prevalence of Epidermolysis Bullosa in Spain
5.2.4.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom
5.2.5.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom
5.2.5.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom
5.3. Japan Epidemiology
5.3.1. Assumptions and Rationale
5.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Japan
5.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Japan
5.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan
6. Treatment and Management of Epidermolysis Bullosa (EB)
6.1. Skin and Wound Management
6.2. General Management Principles
6.3. Special Considerations
6.4. Management of Chronic wounds in EB
6.5. Pain care for patients with epidermolysis bullosa: best care practice guidelines
7. Unmet Needs
8. Emerging Drugs
8.1. Key Cross Competition
8.2. AP-101: Amryt Pharma
8.2.1. Prouduct Description
8.2.2. Other Development Activities
8.2.3. Clinical Development
8.2.4. Clinical Trials Information
8.2.5. Safety and Efficacy
8.2.6. Product Profile
8.3. EB-101: Abeona Therapeutics
8.3.1. Product Description
8.3.2. Other Development Activities
8.3.3. Clinical Development
8.3.4. Clinical Trials Information
8.3.5. Safety and Efficacy
8.3.6. Product Profile
8.4. CCP-020 (Diacerein 1% Ointment): Castle Creek Pharmaceuticals
8.4.1. Product Description
8.4.2. Other Development Activities
8.4.3. Clinical Development
8.4.4. Clinical Trials Information
8.4.5. Safety and Efficacy
8.4.6. Product Profile
8.5. RGN-137: RegeneRx
8.5.1. Product Description
8.5.2. Other Development Activities
8.5.3. Clinical Development
8.5.4. Clinical Trials Information
8.5.5. Safety and Efficacy
8.5.6. Product Profile
8.6. KB103 (Bercolagene Telserpavec): Krystal Biotech
8.6.1. Product Description
8.6.2. Other Development Activities
8.6.3. Clinical Development
8.6.4. Clinical Trials Information
8.6.5. Safety and Efficacy
8.6.6. Product Profile
8.7. FCX-007: Fibrocell Technologies
8.7.1. Product Description
8.7.2. Other Development Activities
8.7.3. Clinical Development
8.7.4. Clinical Trials Information
8.7.5. Safety and Efficacy
8.7.6. Product Profile
8.8. Allo-APZ2-EB: RHEACELL GmbH
8.8.1. Product Description
8.8.2. Other Development Activities
8.8.3. Clinical Development
8.8.4. Clinical Trials Information
8.8.5. Product Profile
8.9. COL7 and LAMB3 gene therapy: Holostem Terapie Avanzate
8.9.1. Product Description
8.9.2. Other Development Activities
8.9.3. Clinical Development
8.9.4. Clinical Trials Information
8.9.5. Safety and Efficacy
8.9.6. Product Profile
8.10. HMGB? peptides: Stemrim
8.10.1. Product Description
8.10.2. Other Development Activities
8.10.3. Product Profile
8.11. Failed Therapies for Epidermolysis Bullosa (EB)
8.12. JR-031: JCR Pharmaceuticals
8.12.1. Product Description
8.12.2. Other Development Activities
8.12.3. Clinical Development
8.12.4. Clinical Trials Information
8.12.5. Product Profile
8.13. Zorblisa: Amicus Therapeutics
8.13.1. Product Description
8.13.2. Other Development Activities
8.13.3. Clinical Development
8.13.4. Clinical Trials Information
8.13.5. Safety and Efficacy
8.13.6. Product Profile
9. Epidermolysis Bullosa: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Epidermolysis Bullosa in the 7MM
9.3. Market Size of Epidermolysis Bullosa by Therapies in the 7MM
10. Market Outlook: The United States
10.1. United States Market Size
10.1.1. The total Market size of Epidermolysis Bullosa
10.1.2. Market Size of Epidermolysis Bullosa by Therapies in the United States
11. Market Outlook: Europe
11.1. Germany
11.1.1. Total Market size of Epidermolysis Bullosa
11.1.2. Market Size of Epidermolysis Bullosa by Therapies in Germany
11.2. France
11.2.1. Total Market size of Epidermolysis Bullosa
11.2.2. Market Size of Epidermolysis Bullosa by Therapies in France
11.3. Italy
11.3.1. Total Market size of Epidermolysis Bullosa
11.3.2. Market Size of Epidermolysis Bullosa by Therapies in Italy
11.4. Spain
11.4.1. Total Market size of Epidermolysis Bullosa
11.4.2. Market Size of Epidermolysis Bullosa by Therapies in Spain
11.5. United Kingdom
11.5.1. Total Market size of Epidermolysis Bullosa
11.5.2. Market Size of Epidermolysis Bullosa by Therapies in the United Kingdom
12. Market Outlook: Japan
12.1. Total Market size of Epidermolysis Bullosa
12.2. Market Size of Epidermolysis Bullosa by Therapies in Japan
13. Market Drivers
14. Market Barriers
15. Appendix
15.1. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight

Epidermolysis Bullosa Market

Epidermolysis Bullosa (EB) - Market Insight, Epidemiology and Market Forecast - 2028

DelveInsight's 'Epidermolysis Bullosa (EB) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidem..